Thiazolopyrimidines are well known to be designed to act as bio-isosteric analogues of purine nucleus. They proved to show a wide range of biological activities; such as anticancer, anti-inflammatory, antifungal, antiviral and antitubercular activity. In this study, a literature survey was thoroughly performed to elect the most active thiazolopyrimidine-containing scaffolds; acting as anticancer agents; to be subjected to extensive computational studies in order to explore the possible credible mode of their anticancer activity. First, drug-likeness was investigated for the most active derivatives, followed by molecular docking study against CDK, VEGFR and PI3K enzymes to assess their binding energy and propose the mode of action. Then, contact preference and surface mapping studies were carried out to explain the presence of remarkable affinity of certain analogues towards a specific enzyme, in addition to providing more information about their activity. Finally, physicochemical properties, Lipinski's rule of five and ADMET prediction studies were applied to predict the best route of administration and to suggest the pharmacokinetics of the most promising candidates.
                    Previous Article in event
            
                            Previous Article in session
            
                    
    
                    Next Article in event
            
                            
                                                    
        
                    Thiazolopyrimidine as a Promising Anticancer Pharmacophore: In Silico Drug Design, Molecular Docking and ADMET prediction Studies
                
                                    
                
                
                    Published:
01 November 2022
by MDPI
in 8th International Electronic Conference on Medicinal Chemistry
session Small molecules as drug candidates
                
                                    
                
                
                    Abstract: 
                                    
                        Keywords: Thiazolopyrimidines; anticancer; computational studies; molecular docking; ADMET prediction
                    
                
                
                
                
        
            